Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1995 Sep;39(9):2073–2077. doi: 10.1128/aac.39.9.2073

Comparison of activities of rifapentine and rifampin against Mycobacterium tuberculosis residing in human macrophages.

N Mor 1, B Simon 1, N Mezo 1, L Heifets 1
PMCID: PMC162883  PMID: 8540718

Abstract

The activities of rifapentine and rifampin against Mycobacterium tuberculosis residing in human monocyte-derived macrophages were determined. The MICs and MBCs of rifapentine for intracellular bacteria were two- to fourfold lower than those of rifampin. For extracellular bacteria, this difference was less noticeable. Nevertheless, the more favorable pharmacokinetics of rifapentine over rifampin was addressed in other experimental models. These models showed substantial differences after short pulsed exposures of the infected macrophages to the drugs and when the infected macrophages were exposed to changing drug concentrations that imitated the pharmacokinetic curves observed in blood. Once-a-week exposures to rifapentine concentrations equivalent to those attained in blood after one 600-mg dose resulted during the first week in a dramatic decline in the number of bacteria, and this decline was maintained at a minimal level for a period of four weeks. The results of this study have shown the suitability of rifapentine for intermittent-treatment regimens. The prolonged effect of rifapentine found in this study may be associated with high ratios of intracellular accumulation, which were four- to fivefold higher than those found for rifampin. Further studies on the intracellular distribution of rifamycins and on the sites of actual interaction between the drugs and bacteria residing in macrophages are necessary.

Full Text

The Full Text of this article is available as a PDF (188.4 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Arioli V., Berti M., Carniti G., Randisi E., Rossi E., Scotti R. Antibacterial activity of DL 473, a new semisynthetic rifamycin derivative. J Antibiot (Tokyo) 1981 Aug;34(8):1026–1032. doi: 10.7164/antibiotics.34.1026. [DOI] [PubMed] [Google Scholar]
  2. Assandri A., Ratti B., Cristina T. Pharmacokinetics of rifapentine, a new long lasting rifamycin, in the rat, the mouse and the rabbit. J Antibiot (Tokyo) 1984 Sep;37(9):1066–1075. doi: 10.7164/antibiotics.37.1066. [DOI] [PubMed] [Google Scholar]
  3. Birmingham A. T., Coleman A. J., Orme M. L., Park B. K., Pearson N. J., Short A. H., Southgate P. J. Antibacterial activity in serum and urine following oral administration in man of DL473 (a cyclopentyl derivative of rifampicin) [proceedings]. Br J Clin Pharmacol. 1978 Nov;6(5):455P–456P. doi: 10.1111/j.1365-2125.1978.tb04626.x. [DOI] [PubMed] [Google Scholar]
  4. Dhillon J., Dickinson J. M., Guy J. A., Ng T. K., Mitchison D. A. Activity of two long-acting rifamycins, rifapentine and FCE 22807, in experimental murine tuberculosis. Tuber Lung Dis. 1992 Apr;73(2):116–123. doi: 10.1016/0962-8479(92)90066-S. [DOI] [PubMed] [Google Scholar]
  5. Dhillon J., Mitchison D. A. Activity in vitro of rifabutin, FCE 22807, rifapentine, and rifampin against Mycobacterium microti and M. tuberculosis and their penetration into mouse peritoneal macrophages. Am Rev Respir Dis. 1992 Jan;145(1):212–214. doi: 10.1164/ajrccm/145.1.212. [DOI] [PubMed] [Google Scholar]
  6. Dickinson J. M., Mitchison D. A. In vitro observations on the suitability of new rifamycins for the intermittent chemotherapy of tuberculosis. Tubercle. 1987 Sep;68(3):183–193. doi: 10.1016/0041-3879(87)90054-7. [DOI] [PubMed] [Google Scholar]
  7. Dickinson J. M., Mitchison D. A. In vitro properties of rifapentine (MDL473) relevant to its use in intermittent chemotherapy of tuberculosis. Tubercle. 1987 Jun;68(2):113–118. doi: 10.1016/0041-3879(87)90026-2. [DOI] [PubMed] [Google Scholar]
  8. Easmon C. S., Crane J. P. Comparative uptake of rifampicin and rifapentine (DL473) by human neutrophils. J Antimicrob Chemother. 1984 Jun;13(6):585–591. doi: 10.1093/jac/13.6.585. [DOI] [PubMed] [Google Scholar]
  9. Heifets L. B., Lindholm-Levy P. J., Flory M. A. Bactericidal activity in vitro of various rifamycins against Mycobacterium avium and Mycobacterium tuberculosis. Am Rev Respir Dis. 1990 Mar;141(3):626–630. doi: 10.1164/ajrccm/141.3.626. [DOI] [PubMed] [Google Scholar]
  10. Ji B., Truffot-Pernot C., Lacroix C., Raviglione M. C., O'Brien R. J., Olliaro P., Roscigno G., Grosset J. Effectiveness of rifampin, rifabutin, and rifapentine for preventive therapy of tuberculosis in mice. Am Rev Respir Dis. 1993 Dec;148(6 Pt 1):1541–1546. doi: 10.1164/ajrccm/148.6_Pt_1.1541. [DOI] [PubMed] [Google Scholar]
  11. Mor N., Vanderkolk J., Heifets L. Inhibitory and bactericidal activities of levofloxacin against Mycobacterium tuberculosis in vitro and in human macrophages. Antimicrob Agents Chemother. 1994 May;38(5):1161–1164. doi: 10.1128/aac.38.5.1161. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Mor N., Vanderkolk J., Mezo N., Heifets L. Effects of clarithromycin and rifabutin alone and in combination on intracellular and extracellular replication of Mycobacterium avium. Antimicrob Agents Chemother. 1994 Dec;38(12):2738–2742. doi: 10.1128/aac.38.12.2738. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Nibbering P. H., Zomerdijk T. P., Corsèl-Van Tilburg A. J., Van Furth R. Mean cell volume of human blood leucocytes and resident and activated murine macrophages. J Immunol Methods. 1990 May 8;129(1):143–145. doi: 10.1016/0022-1759(90)90432-u. [DOI] [PubMed] [Google Scholar]
  14. Pascual A., Tsukayama D., Kovarik J., Gekker G., Peterson P. Uptake and activity of rifapentine in human peritoneal macrophages and polymorphonuclear leukocytes. Eur J Clin Microbiol. 1987 Apr;6(2):152–157. doi: 10.1007/BF02018197. [DOI] [PubMed] [Google Scholar]
  15. Truffot-Pernot C., Grosset J., Bismuth R., Lecoeur H. Activité de la rifampicine administrée de manière intermittente et de la cyclopentyl rifamycine (ou DL473) sur la tuberculose expérimentale de la souris. Rev Fr Mal Respir. 1983;11(6):875–882. [PubMed] [Google Scholar]
  16. Tsukamura M., Mizuno S., Toyama H. [In-vitro antimycobacterial activity of rifapentine (comparison with rifampicin)]. Kekkaku. 1986 Dec;61(12):633–639. [PubMed] [Google Scholar]
  17. Yates M. D., Collins C. H. Comparison of the sensitivity of mycobacteria to the cyclopentyl rifamycin DL473 and rifampicin. J Antimicrob Chemother. 1982 Aug;10(2):147–150. doi: 10.1093/jac/10.2.147. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES